Getting Things Moving: Opportunities In Opioid-Induced Constipation
Executive Summary
With relatively few new drugs in development for opioid-induced constipation, the category is wide open for new entrants to conduct clinical studies and make a difference for patients; a Market Spotlight report from Datamonitor Healthcare reviews the indication's outlook.
You may also be interested in...
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.
Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy
Mallinckrodt is to acquire Sucampo Pharmaceuticals for about $1.2bn. The deal brings it a short-term sales boost from Amitiza, although the constipation treatment only has a few years left before generic competition hits. Longer-term hopes lie in two Phase III products for rare diseases.
Purdue Highlights Convenience Of New Opioid Induced Constipation Drug Symproic
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.